Sökning: WFRF:(Kormos L. L.) >
Daclizumab to preve...
Daclizumab to prevent rejection after cardiac transplantation.
-
Hershberger, Ray E (författare)
-
Starling, Randall C (författare)
-
Eisen, Howard J (författare)
-
visa fler...
-
- Bergh, Claes-Håkan, 1951 (författare)
- Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Wallenberglaboratoriet,Cardiovascular Institute,Wallenberg Laboratory
-
Kormos, Robert L (författare)
-
Love, Robert B (författare)
-
Van Bakel, Adrian (författare)
-
Gordon, Robert D (författare)
-
Popat, Rina (författare)
-
Cockey, Louise (författare)
-
Mamelok, Richard D (författare)
-
visa färre...
-
(creator_code:org_t)
- 2005
- 2005
- Engelska.
-
Ingår i: The New England journal of medicine. - 1533-4406. ; 352:26, s. 2705-13
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: Daclizumab, a humanized monoclonal antibody against the interleukin-2 receptor, reduced the risk of rejection without increasing the risk of infection among renal-transplant recipients and, in a single-center trial, among cardiac-transplant recipients. We conducted a multicenter, placebo-controlled, double-blind study to confirm these results in cardiac-transplant patients. METHODS: We randomly assigned 434 recipients of a first cardiac transplant treated with standard immunosuppression (cyclosporine, mycophenolate mofetil, and corticosteroids) to receive five doses of daclizumab or placebo. The primary end point was a composite of moderate or severe cellular rejection, hemodynamically significant graft dysfunction, a second transplantation, or death or loss to follow-up within six months. RESULTS: By six months, 104 of 218 patients in the placebo group had reached the primary end point, as compared with 77 of the 216 patients in the daclizumab group (47.7 percent vs. 35.6 percent, P=0.007), a 12.1 percent absolute risk reduction and a 25 percent relative reduction. The rate of rejection was lower in the daclizumab group than in the placebo group (41.3 percent vs. 25.5 percent). Among patients reaching the primary end point, the median time to the end point was almost three times as long in the daclizumab group as in the placebo group during the first 6 months (61 vs. 21 days) and at 1 year (96 vs. 26 days). More patients in the daclizumab group than in the placebo group died of infection (6 vs. 0) when they received concomitant cytolytic therapy. CONCLUSIONS: Daclizumab was efficacious as prophylaxis against acute cellular rejection after cardiac transplantation. Because of the excess risk of death, concurrent or anticipated use of cytolytic therapy with daclizumab should be avoided.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kirurgi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Surgery (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
Nyckelord
- Adolescent
- Adrenal Cortex Hormones
- therapeutic use
- Adult
- Aged
- Antibodies
- Monoclonal
- adverse effects
- therapeutic use
- Cyclosporine
- therapeutic use
- Double-Blind Method
- Drug Therapy
- Combination
- Female
- Graft Rejection
- epidemiology
- prevention & control
- Heart Transplantation
- mortality
- Humans
- Immunoglobulin G
- adverse effects
- therapeutic use
- Immunosuppressive Agents
- adverse effects
- therapeutic use
- Logistic Models
- Male
- Middle Aged
- Mycophenolic Acid
- analogs & derivatives
- therapeutic use
- Opportunistic Infections
- epidemiology
- microbiology
- mortality
- Survival Analysis
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Hershberger, Ray ...
-
Starling, Randal ...
-
Eisen, Howard J
-
Bergh, Claes-Håk ...
-
Kormos, Robert L
-
Love, Robert B
-
visa fler...
-
Van Bakel, Adria ...
-
Gordon, Robert D
-
Popat, Rina
-
Cockey, Louise
-
Mamelok, Richard ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kirurgi
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Farmakologi och ...
- Artiklar i publikationen
-
The New England ...
- Av lärosätet
-
Göteborgs universitet